Patents by Inventor Michael E. Garst

Michael E. Garst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYCLOSPORIN DERIVATIVES FOR ENHANCING THE GROWTH OF HAIR
    Publication number: 20100305047
    Abstract: The present invention provides a method for the treatment of alopecia and/or enhancing hair growth in a patient, wherein said method comprises administering, preferably topically, to the skin, e.g. the scalp or the eyelid, a therapeutically effective amount of a cyclosporin A derivative selected from the group consisting of compounds represented by the formula: wherein R1 is S-Alk-R wherein Alk is an alkylene or alkylenyl linkage, R is a hydrogen or a unsubstituted or substituted hydrocarbyl group and R2 is selected from the group consisting of hydroxyl, lower alkyl and hydroxyl substituted lower alkyl.
    Type: Application
    Filed: May 21, 2010
    Publication date: December 2, 2010
    Applicant: ALLERGAN, INC.
    Inventors: David F. Woodward, Michael E. Garst
  • UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME
    Publication number: 20100298395
    Abstract: Compounds of Formula 1 where the variables have the meaning defined in the specification are used to activate alpha2 adrenergic receptors. The compounds of Formula 1 are incorporated in pharmaceutical compositions and are used as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2 adrenergic receptors.
    Type: Application
    Filed: August 3, 2010
    Publication date: November 25, 2010
    Applicant: ALLERGAN, INC.
    Inventors: Todd M. Heidelbaugh, Ken Chow, Phong X. Nguyen, Daniel W. Gil, John E. Donello, Michael E. Garst, Larry A. Wheeler, John R. Cappiello
  • 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
    Patent number: 7838545
    Abstract: Compounds of Formula 1 where the variables have the meaning defined in the specification are agonists of alpha2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors. Additionally some of the claimed compounds have no or only minimal cardiovascular and/or sedatory activity. The compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2 adrenergic receptors. Compounds of Formula 1 which have no significant cardiovascular and/or sedatory activity are useful for treating pain and other conditions with minimal side effects.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: November 23, 2010
    Assignee: Allergan, Inc.
    Inventors: Todd M. Heidelbaugh, Ken Chow, Phong X. Nguyen, Daniel W. Gill, John E. Donello, Michael E. Garst, Larry A. Wheeler
  • Substituted 2-aminotetralin derivatives as selective alpha 2B agonist
    Patent number: 7829587
    Abstract: Substituted 2-aminotetralin derivatives as selective alpha 2B agonists can be incorporated in a pharmaceutical composition and can be used in methods of treating an alpha 2B receptor mediated diseases or conditions. The compounds are represented by Formula 1: wherein R1=H, methyl, ethyl, propyl, or cyclobutyl; R2=methyl or H; R3=pyridinyl X=C or O.
    Type: Grant
    Filed: January 9, 2008
    Date of Patent: November 9, 2010
    Assignee: Allergan, Inc.
    Inventors: John R. Cappiello, Dario G. Gomez, Ken Chow, Michael E. Garst, Daniel W. Gil, Larry A. Wheeler
  • ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS
    Publication number: 20100273814
    Abstract: Disclosed herein is a compound of the formula wherein A and B are described herein. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
    Type: Application
    Filed: May 13, 2008
    Publication date: October 28, 2010
    Inventors: Santosh C. Sinha, Todd M. Heidelbaugh, Ken Chow, Smita S. Bhat, Phong X. Nguyen, Michael E. Garst
  • Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same
    Patent number: 7795292
    Abstract: Compounds of Formula 1 where the variables have the meaning defined in the specification are used to activate alpha2 adrenergic receptors. The compounds of Formula 1 are incorporated in pharmaceutical compositions and are used as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2 adrenergic receptors.
    Type: Grant
    Filed: September 20, 2005
    Date of Patent: September 14, 2010
    Assignee: Allergan, Inc.
    Inventors: Todd M. Heidelbaugh, Ken Chow, Phong X. Nguyen, Daniel W. Gil, John E. Donello, Michael E. Garst, Larry A. Wheeler, John R. Cappiello
  • THERAPEUTIC ((PHENYL)IMIDAZOLYL)METHYLQUINOLINYL COMPOUNDS
    Publication number: 20100197729
    Abstract: Disclosed herein is a compound of the formula (I) therapeutic methods, compositions, and medicaments related thereto are also disclosed.
    Type: Application
    Filed: May 21, 2008
    Publication date: August 5, 2010
    Applicant: ALLERDAN, INC.
    Inventors: Santosh C. Sinha, Todd M. Heidelbaugh, Ken Chow, Smita S. Bhat, Michael E. Garst
  • Therapeutic ((Bicylicheteroaryl)Imidazolyl) Methylheteroaryl Compounds
    Publication number: 20100190823
    Abstract: Disclosed herein is a compound of the formula (I) therapeutic methods, compositions, and medicaments related thereto are also disclosed.
    Type: Application
    Filed: May 21, 2008
    Publication date: July 29, 2010
    Applicant: ALLEGERGAN INC.
    Inventors: Santosh C. Sinha, Todd M. Heidelbaugh, Ken Chow, Smita S. Bhat, Phong X. Nguyen, Michael E. Garst
  • Methods and compositions for modulating alpha adrenergic receptor activity
    Patent number: 7754768
    Abstract: Methods and compositions for the treatment of pain and intraocular pressure. Particularly disclosed are new compositions for the treatment of chronic pain, glaucoma and methods for their use.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: July 13, 2010
    Assignee: Allergan, Inc.
    Inventors: Ken Chow, Daniel W. Gil, Wenkui Ken Fang, Michael E. Garst, Larry A. Wheeler
  • N-(1-PHENYL-2-ARYLETHYL)-4,5-DIHYDRO-2H-PYRROL-5-AMINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B OR ALPHA2B AND ALPHA2C ADRENOCEPTORS
    Publication number: 20100145061
    Abstract: The present invention provides compounds which are N-(1-phenyl-2-arylethyl)-4,5-dihydro-2H-pyrrol-5-amine compounds and are subtype selective modulators of alpha 2B or alpha 2B and alpha 2C adrenoreceptors and are selected from the group of compounds represented by the formula
    Type: Application
    Filed: December 7, 2009
    Publication date: June 10, 2010
    Applicant: ALLERGAN, INC.
    Inventors: Ken Chow, Janet A. Takeuchi, Ling Li, Todd M. Heidelbaugh, Phong X. Nguyen, Evelyn G. Corpuz, Wenkui K. Fang, Santosh C. Sinha, Michael E. Garst
  • QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS
    Publication number: 20100113516
    Abstract: Disclosed herein is a compound of the formula (I):(I). Therapeutic methods, compositions and medicaments related thereto are also disclosed.
    Type: Application
    Filed: January 4, 2008
    Publication date: May 6, 2010
    Applicant: Allergan, Inc.
    Inventors: Todd M. Heidelbaugh, Phong X. Nguyen, Ken Chow, Michael E. Garst
  • Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety
    Publication number: 20100113524
    Abstract: The compounds of the formulas (I), (II), (III) and (IV), where the symbols are as defined in the specification are prodrugs of proton pump inhibitors. The R4 group includes at least one acidic group or its pharmaceutically acceptable salt, and the compound having the R4 group have improved aqueous solubility, stability in plasma and improved bioavailability.
    Type: Application
    Filed: September 15, 2007
    Publication date: May 6, 2010
    Inventors: Michael E. Garst, George Sachs, Jai Moo Shin
  • Therapeutic fluoroethyl ureas
    Patent number: 7709507
    Abstract: Compounds of the formula or a pharmaceutically acceptable salt thereof or a tautomer thereof, wherein A and B are as described herein, are useful for treating conditions afflicting mammals.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: May 4, 2010
    Assignee: Allergan, Inc.
    Inventors: Ken Chow, Wenkui K. Fang, Evelyn G. Corpuz, Daniel W. Gil, Michael E. Garst
  • SUBSTITUTED 3-AMINO-1-OXO OR THIOXO-1,2,5,6,7,8-HEXAHYDRO-2,7-NAPHTHYRIDINE-4-CARBONITRILES ARE SELECTIVE ALPHA 2B ANTAGONISTS
    Publication number: 20100076194
    Abstract: The present invention provides compounds which are subtype selective antagonists of the alpha 2B adrenergic receptor and have no or weak antagonist activity at the other alpha adrenergic receptors. These compounds are useful as tool compounds and, in particular, as tool compounds for developing compounds useful in treating diseases that include but are not limited to chronic pain, visceral pain, corneal pain, neuropathic pain, glaucoma, ischemic neuropathies and other neurodegenerative diseases and conditions. These compounds are also useful as compounds for treating myocardial infarction and preventing acute coronary events. The compounds of this invention are 3-amino-1-thioxo or oxo-1,2,5,6,7,8-hexahydro-2,7-naphthyridine-4-carbonitriles or substituted derivatives thereof.
    Type: Application
    Filed: September 4, 2009
    Publication date: March 25, 2010
    Applicant: ALLERGAN, INC.
    Inventors: John R. CAPPIELLO, Ken CHOW, Todd M. HEIDELBAUGH, Janet A. TAKEUCHI, Michael E. GARST, Daniel W. GIL, Karen M. KEDZIE, John E. DONELLO
  • QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS
    Publication number: 20100076020
    Abstract: Disclosed herein is a compound of the formula (I): (I). Therapeutic methods, compositions and medicaments related thereto are also disclosed.
    Type: Application
    Filed: January 4, 2008
    Publication date: March 25, 2010
    Applicant: Allergan, INC.
    Inventors: Todd M. Heidelbaugh, Phong X. Nguyen, Ken Chow, Michael E. Garst
  • 4-(Phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
    Patent number: 7683089
    Abstract: Compounds of Formula 1 where the variables have the meaning defined in the specification are agonists of alpha2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors. Additionally some of the claimed compounds have no or only minimal cardivascular and/or sedatory activity. The compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2 adrenergic receptors. Compounds of Formula 1 which have no significant cardiovascular and/or sedatory activity are useful for treating pain and other conditions with minimal side effects.
    Type: Grant
    Filed: September 20, 2005
    Date of Patent: March 23, 2010
    Assignee: Allergan, Inc
    Inventors: Todd M. Heidelbaugh, Ken Chow, Phong X. Nguyen, Daniel W. Gil, John E. Donello, Michael E. Garst, Larry A. Wheeler
  • CYCLOSPORIN DERIVATIVES FOR TREATING OCULAR AND DERMAL DISEASES AND CONDITIONS
    Publication number: 20100009953
    Abstract: The present invention provides a method for the treatment of ocular or dermal diseases and/or conditions, e.g. an aqueous deficient dry eye state, uveitis or phacoanaphylactic endophthalmitis in an eye, or balanitis, psoriasis, or atopic dermatitis of the skin, said method comprising administering, topically to the eye or the skin, a therapeutically effective amount of a novel cyclosporin A derivative selected from the group consisting of compounds represented by the formula: wherein R1 is S-Alk-R wherein Alk is an alkylene linkage, preferably a methylene or poly methylene linkage, e.g. a C2 to C6 polymethylene linkage, or a polyalkenylene linkage, e.g. a C3 to C6 alkenylenyl linkage, R is R is —N?C(NR3R4)(NR5R6) or NR7[(NR3R4)C?NR5], i.e. guanidines or —N?C(R8)(NR9R10), i.e.
    Type: Application
    Filed: July 9, 2009
    Publication date: January 14, 2010
    Applicant: ALLERGAN, INC.
    Inventor: Michael E. Garst
  • THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS
    Publication number: 20100009985
    Abstract: Disclosed herein are compounds represented by the structural formula: therapeutic methods, compositions, and medicaments related thereto are also disclosed.
    Type: Application
    Filed: May 7, 2009
    Publication date: January 14, 2010
    Applicant: ALLERGAN, INC.
    Inventors: Santosh C. SINHA, Smita S. BHAT, Ken CHOW, Richard L. BEARD, John E. DONELLO, Michael E. GARST
  • NAPHTHYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS
    Publication number: 20100004305
    Abstract: Disclosed herein is a compound of the formula (a): Therapeutic methods, compositions and medicaments related thereto are also disclosed.
    Type: Application
    Filed: January 4, 2008
    Publication date: January 7, 2010
    Inventors: Todd M. Heidelbaugh, Phong X. Nguyen, Ken Chow, Michael E. Garst
  • BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR
    Publication number: 20090312305
    Abstract: A compound represented by the structural formula: Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
    Type: Application
    Filed: May 18, 2009
    Publication date: December 17, 2009
    Applicant: ALLERGAN, INC.
    Inventors: Richard L. Beard, Tien T. Duong, Thong H. Vu, Vidyasagar Voligonda, John E. Donello, Michael E. Garst, Gerard A. Rodrigues